文献速递瓣膜外科

标准化主动脉瓣新瓣叶成形术治疗主动脉瓣疾病

Standardized Aortic Valve Neocuspidization for Treatment of Aortic Valve Diseases.
PubMed 文献 · Ann Thorac Surg · 2022-04-18

本文综述使用戊二醛处理的自体心包的主动脉瓣新瓣叶成形术(AVNeo,即Ozaki手术)的文献,涵盖适应证、结局、潜在获益与重建瓣膜失效模式。文献报告早期死亡率为0%至5.88%,最大队列850例院内死亡率为1.88%,累积再次手术率为4.2%。作者认为AVNeo是生物瓣主动脉瓣置换的多功能标准化替代方案,但需长期结局与临床试验数据。

要点

  • AVNeo使用戊二醛处理的自体心包重建主动脉瓣,即Ozaki手术。
  • 文献报告早期死亡率为0%至5.88%,最大队列850例院内死亡率为1.88%。
  • 最大系列中主动脉瓣再次手术累积发生率为4.2%,多因感染性心内膜炎或瓣膜退变。

核心结论

  • 主动脉瓣新瓣叶成形术是生物瓣主动脉瓣置换的多功能且标准化的替代方案。
  • 多个中心的早中期结局优良,显示该手术的安全性与耐久性。
  • 需长期结局与临床试验数据以确定哪些患者获益最大。

研究设计与样本

  • 本文为文献综述,检索与主动脉瓣修复、AVNeo或Ozaki手术相关的关键词。
  • 综述所有描述AVNeo实施的文献。
  • 综述对象为使用戊二醛处理的自体心包行AVNeo的已发表文献。

主要发现

  • 文献报告的AVNeo术后早期死亡率为0%至5.88%。
  • 文献中最大队列包括850例患者,院内死亡率为1.88%。
  • 最大系列中主动脉瓣再次手术的累积发生率为4.2%。
  • 再次手术不常见,主要原因为感染性心内膜炎或重建瓣膜退变,退变最常表现为主动脉瓣反流而非狭窄。

关键数值与推荐

  • 早期死亡率:0%至5.88%。
  • 最大队列850例,院内死亡率1.88%。
  • 最大系列主动脉瓣再次手术累积发生率4.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需长期结局与临床试验数据以确定哪些患者获益最大。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortic valve replacement is the traditional surgical treatment for aortic valve diseases, yet standardized aortic valve neocuspidization (AVNeo) is a promising alternative that is gaining popularity. The purpose of this article is to review the available published literature of AVNeo using glutaraldehyde-treated autologous pericardium, also known as the Ozaki procedure, including indications, outcomes, potential benefits, and modes of failure for the reconstructed valve. METHODS: A comprehensive literature search was performed using keywords related to aortic valve repair, AVNeo, or Ozaki procedure. All articles describing performance of AVNeo were reviewed. RESULTS: Reported early mortality after AVNeo varies from 0% to 5.88%. The largest cohort of patients in the literature includes 850 patients with an inhospital mortality rate of 1.88%. Cumulative incidence of aortic valve reoperation was 4.2% in the largest series. Reoperation was uncommon and mainly due to infective endocarditis or degeneration of the reconstructed valve (most commonly due to aortic valve regurgitation, rather than stenosis). CONCLUSIONS: Aortic valve neocuspidization is a versatile and standardized alternative to aortic valve replacement with a biological prosthesis. Early to midterm outcomes from a number of centers are excellent and demonstrate the safety and durability of the procedure. Long-term outcomes and clinical trial data are necessary to determine which patients benefit the most from this procedure.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Amabile A, Krane M, Dufendach K, et al. Standardized Aortic Valve Neocuspidization for Treatment of Aortic Valve Diseases. Ann Thorac Surg. 2022. PMID: 35439450. doi:10.1016/j.athoracsur.2022.03.067

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。